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Abstract 
 
Aim:      To determine whether telephone support using an evidence-based protocol for chronic 
heart failure (CHF) management will improve patient outcomes and will reduce hospital 
readmission rates in patients without access to hospital-based management programs.  
 
Methods:      The rationale and protocol for a cluster-design randomised controlled trial (RCT) of a 
semi-automated telephone intervention for the management of CHF, the Chronic Heart-failure 
Assistance by Telephone (CHAT) Study is described. Care is coordinated by trained cardiac 
nurses located in Heartline, the national call center of the National Heart Foundation of Australia in 
partnership with patients’ general practitioners (GPs).  
 
Conclusions:      The CHAT Study model represents a potentially cost-effective and accessible 
model for the Australian health system in caring for CHF patients in rural and remote areas. The 
system of care could also be readily adapted for a range of chronic diseases and health systems.  
 
Key words: chronic disease management; chronic heart failure; integrated health care systems; 
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Introduction 
 
Chronic heart failure (CHF) is a major public health problem. It is associated with a worse prognosis than most 
cancers and requires frequent, prolonged, and costly admissions to hospital.1,2 The associated burden is 
particularly high in the elderly (Fig. 1).3 Increasing prevalence of CHF as well as the associated personal and 
economic burden mandate consideration and evaluation of new and innovative care models.4–6 As 
demonstrated by the recent DIAL trial undertaken in Argentina, clinical management augmented by specialist 
CHF nurses providing telephone support is one important approach and is clearly a system of care accessible to 
rural and remote patients.7–9  
 
 
Materials and methods 
 
Study design 
 
The chronic heart-failure assistance by telephone (CHAT) Study is a randomised trial of 534 people diagnosed 
with CHF in which all participants will receive standard care (SC) but half will receive a nurse-coordinated 
telephone intervention package (SC + I). This will use interactive voice response (IVR) software known as the 
TeleWatchTM telemedicine system developed by the Johns Hopkins University, USA.10 The nurse-coordinated 
telephone intervention package will be provided by experienced cardiac-trained registered nurses located in the 
National Heart Foundation of Australia call center – Heartline. A major component of the intervention package is 
in the form of prerecorded telephone CHF management scripts based on the Australian national guidelines for 
both the pharmacological and non-pharmacological management of CHF.11 The TeleWatchTM system is a 
telephone-based, semi-automated telemedicine system that enables a limited resource of health care providers, 
namely nurses, to monitor symptoms and support a larger than usual caseload of CHF patients. 
 
Study aims and objectives 
 
The primary aim of the CHAT study is to develop an effective preventative and supportive management strategy 
for Australians with CHF, particularly those residing in rural and remote communities. The study will test this aim 
by determining whether telephone support, involving outpatient education and monitoring using a 
multidisciplinary clinical protocol-based approach for the management of CHF will improve patients’ health status 
as represented by an innovative clinical composite score. Secondary aims include comparing total hospitalized 
days, the proportion of patients on target doses of angiotensin converting enzyme (ACE) inhibitors and changes 
in brain natriuretic peptide (BNP) levels. The cost-effectiveness of the intervention will also be determined.12 
 
Study population 
 
The study is currently recruiting Australia-wide with a target sample size of 534 CHF patients who are being 
predominantly cared for in rural and remote general practices as defined by Rural, Remote, Metropolitan Areas 
(RRMA) classification 3–7 and/or patients from RRMA classification 1 and 2 where access to formal CHF 
management programs is limited or inaccessible.13 
 
General practititoners were self-selected for enrolment. Initially, the study was widely publicised to the Australian 
general practice population through various general practice networks and journals. GPs listed on national 
databases were sent a one-page ‘expression of interest’ fax-back letter of invitation. A member of the research 
team then contacted interested GPs regarding enrolment. 
 
GP randomization 
 
The general practice will be the unit of randomization. A cluster randomization trial is the design of choice aimed 
to prevent contamination between patient study groups. Once the GP has been assigned randomly to either the 
intervention or standard care study group, all patients recruited from that GP’s practice will automatically be 
assigned to the same study group. Participating practices will first be stratified by RRMA before being randomly 
allocated to the standard care or intervention group. 
 
Patient recruitment 
 
Appropriate to a cluster-design randomised controlled trial conducted in general practice, all patients from a 
single practice are assigned to the same study arm. The GP will act as guardian for their consenting patients in 
so far as their participating patients will consent without knowing to which study group their GP practice has 
already been allocated. Enrolling patients will only be given details of this assignment once informed consent 
has been provided and included only once the selection criteria have been met (Table 1). Randomised GPs will 
be asked to enrol between two and 10 CHF patients per practice. 
 
Intervention vs. standard care 
 
Intervention package for patients, their families and carers 
 
Half of the patient population will be randomly assigned to the intervention group and will receive a nurse-
coordinated, CHF-focused intervention package. Each participant in this group will receive initial training in 
telephone calling from the ‘CHAT nurse’ to ensure competence in the independent utilization of the TeleWatchTM 
system technology. Once demonstrated, they will be instructed to call in, using a free-call 1800 number at no 
less than monthly intervals for a 12-month period (Fig. 2). 
 
Responses entered by the patient are individually assessed by preprogramming of the TeleWatchTM system 
according to the patient’s overall health assessment and color-coded according to severity of signs and 
symptoms of worsening CHF (Fig. 3). The patient has the choice to leave a voice message for the nurse or to 
request a telephone follow-up call. The frequency of patient calls is monitored and recorded to allow for the 
exploration of a ‘dose effect’. We hypothesize a positive correlation between the frequency of calls and the effect 
of the intervention. Patients are more likely to learn skills associated with increased self-care activity the more 
feedback and reinforcement they receive through interacting with both the TeleWatchTM system and the CHAT 
nurses. 
 
Participants and their families will be provided with an action plan on how to detect clinical deterioration and 
when and how to access emergency medical care and a personal copy of a Heart Foundation publication Let’s 
Talk about Heart Failure, prepared specifically for this study, and includes a lay-person’s version of the CHF 
national guidelines.14 They will also receive regular newsletters with helpful hints and information relating to their 
involvement in the study and will be given a individualized CHAT study patient diary to record all relevant clinical 
information, including visits to health services. 
 
Intervention package for GPs 
 
Each physician randomised to the intervention group will receive copies of the national guidelines for CHF 
management,11 and the ‘Diuretic Treatment Regimen’,15 a laminated double-sided desktop version of the CHF – 
Clinical Practice Guidelines for quick reference, ongoing targeted contemporary educational materials and 
regular study newsletters. The CHAT nurse will activate the GP fax-back feedback loop to report participants’ 
changing signs and symptoms to their GP (Fig. 4),16 and will activate a study-specific diuretic algorithm designed 
to maintain patients when they are not able to access their GPs.15 
 
Standard care package for patients, their families and carers 
 
General practitioners assigned to the standard care group will receive copies of the national guidelines for CHF 
management and the ‘Diuretic Treatment Regimen’.15,17 Their patients will receive an individualized CHAT 
Study patient diary but no other literature.  
 
To assist with the development of the therapeutic relationship, reported as being more difficult where physical 
contact is precluded, personal and professional profiles including a photograph of the telephone support nurse 
and the independent evaluator working within the call center environment will be provided to all participants. 
 
Patient follow-up 
 
Participant contact will be at least monthly for a minimum of 12 months. The nurse-coordinated telephone 
intervention follow-up will be supported by specific CHF management training decision support software, the 
TeleWatchTM telemedicine system.10 Telephone surveys will be used to evaluate study clinical endpoints and 
will be administered at baseline, 6 months and 12 months by a trained independent interviewer who remains 
blinded with regard to patients’ treatment allocations. The survey will include questions relating to quality of life, 
economic assessment and utilization of health services. 
 
Endpoint evaluations 
 
The primary outcome variable will be a clinical composite (Packer) score,18 which combines changes in New 
York Heart Association class and the patient’s ‘global’ assessment. This latter measure asks the patient to judge 
whether their overall health status has changed since the commencement of the study and if so, to define the 
direction and estimate the magnitude of the change. Also included within the Packer composite score is the 
occurrence of major clinical events such as hospital admissions for or with CHF, all-cause mortality and 
withdrawal from intervention due to worsening heart failure within the study period. 
 
Key secondary evaluations include total hospitalized days and patient quality of life (Table 2). Physiological 
evaluation of the intervention will be determined by BNP analysis. Both primary and secondary outcomes will 
also be compared in urban (RRMA 1–2) and rural and remote (RRMA 3–7) patients. 
 
Data analysis and statistical methods 
 
The primary outcome or Packer composite score is comprised of the following values: improved, no change or 
worsened. For example, assuming patients in the standard care arm would respond as 25% improved, 50% no 
change, 25% worsened, an odds ratio of 1.65 in a proportional odds model would improve the scores in the 
intervention arm to 36% improved, 48% no change, and 16% worsened. With patients individually randomised, 
to detect this change with 80% power would require 222 patients per arm. With an average of three patients per 
practice in a cluster-randomised design, an intrapractice correlation of 0.10, and applying the design effect for 
interval-scaled measures, the approximate sample size inflation factor is 20%, leading to a total sample size of 
267 patients per arm. 
 
Cost–effectiveness analysis 
 
Cost-effectiveness will be assessed in a marginal analysis from a health system perspective, that is, including all 
private and public health service costs. The costs of the intervention and the cost offsets from reduced hospital 
admissions will be assessed from detailed data prospectively collected on drug utilization, investigations, 
hospital admissions, attendances at emergency departments and general practitioners (scheduled and 
unscheduled). This data will be supplemented using the Health Insurance Commission (HIC) and Department of 
Veterans’ Affairs (DVA). 
 
The measure of health outcome will be derived from mortality outcomes and differences in quality of life (as 
measured by the Euroqol, a generic measure of health-related quality of life)19 and will be expressed in quality-
adjusted life years (QALYs). The resultant cost-utility ratios (cost per QALY) can easily be redefined as a cost 
per disability adjusted life years (DALYs) because the disability weights used in the Australian Burden of Disease 
studies were derived for health states with a Euroqol description.20 All analyses will be on an intention-to-treat 
basis.  
 
 
Discussion 
 
Many clinical trials in CHF, whether of non-pharmacological or pharmacological therapies, including the recently 
published DIAL trial exclude up to 40% of the patients screened for the intervention on the basis of factors such 
as comorbid conditions and lack of proximity to the study center.21–23 Traditional empiricism demands 
homogeneity, but the reality is that in the community, CHF patients are heterogeneous.24,25 On the basis of 
these observations and a fundamental premise of the study which relates to the accessibility of care, in contrast 
to the DIAL trial, inclusion criteria have been designed to recruit a population that truly reflects ‘real world’ 
community practice, including patients with diastolic dysfunction. General practitioners will be recruited from 
practices identified by the RRMA to ensure the representative nature of study participants and will continue to 
provide ‘usual care’ during the 1-year study period. Recruitment will occur predominantly from RRMA 
classification 3–7 (rural and remote) general practices where access to formal CHF management programs is 
currently largely unavailable. 
 
The inclusion of BNP as an objective measure will provide an opportunity to undertake a physiological evaluation 
of the intervention, which has not previously been evaluated in this manner, and to assess the prognostic 
capability of BNP within a CHF community-based patient population. 
 
This is also the first study of its type where the participants are instructed to telephone the nurse rather than 
receive nurse-initiated telephone calls, which potentially could translate to care being provided for those in 
greatest need. 
 
The CHAT study will also test a novel integrated and semiautomated IT support platform that enables patients to 
telephone as often as they choose, and at a time which suits them best. This automated service is aimed to help 
monitor patients’ progress and reinforce CHF self-care skills and activities while requiring fewer nurses than a 
traditional telephone-based health service.9  
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Summary of implications for GPs 
 
Compounding the pressure of a shrinking general practice (GP) workforce, Australia’s ageing population 
mandates the consideration and evaluation of new models of care. There is a growing expectation that GPs will 
play an increasing role in chronic disease management. The CHAT Study will test an innovative and affordable 
‘system-of-care’ designed to support GPs and their patients with chronic heart failure (CHF). Many patients have 
limited access to formal CHF management programs, particularly in rural and remote areas. Through recruiting a 
population that truly reflects ‘real world’ community practice, this study will test the capacity of telenursing to 
support GPs, improve CHF patients’ quality of life and reduce their need for hospital readmission.  
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Table 1 - Patient selection criteria 
 
Table 2 - Outcome measures 
 
 
 
 
 
 
 
 
Figure 1 Projected numbers of older patients with coronary heart disease, high blood pressure 
and heart failure in Australia26 (With permission from Prof D. Kelly and Circulation)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2 CHAT Study schema
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3 Operation of the TeleWatchTM system
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 4 CHAT Study GP feedback loop
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